Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 220.25 Million EUR | -13.91% |
| 2022 | 255.84 Million EUR | 40.91% |
| 2021 | 181.57 Million EUR | 143.13% |
| 2020 | 74.68 Million EUR | 74.32% |
| 2019 | 42.84 Million EUR | 145.41% |
| 2018 | 17.45 Million EUR | -8.16% |
| 2017 | 19 Million EUR | -32.83% |
| 2016 | 28.3 Million EUR | 29.57% |
| 2015 | 21.84 Million EUR | -21.13% |
| 2014 | 27.69 Million EUR | 8.72% |
| 2013 | 25.47 Million EUR | 17.51% |
| 2012 | 21.67 Million EUR | 14.18% |
| 2011 | 18.98 Million EUR | -26.99% |
| 2010 | 26 Million EUR | 87.09% |
| 2009 | 13.89 Million EUR | -50.92% |
| 2008 | 28.32 Million EUR | 53.6% |
| 2007 | 18.43 Million EUR | 427.86% |
| 2006 | 3.49 Million EUR | -100.0% |
| 2005 | 291.58 Billion EUR | 17158.37% |
| 2004 | 1.68 Billion EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 37.18 Million EUR | 92.69% |
| 2024 Q1 | 19.29 Million EUR | -71.13% |
| 2023 Q4 | 66.84 Million EUR | -1.99% |
| 2023 Q2 | 24.47 Million EUR | -59.69% |
| 2023 FY | 220.25 Million EUR | -13.91% |
| 2023 Q3 | 68.2 Million EUR | 178.62% |
| 2023 Q1 | 60.72 Million EUR | -38.67% |
| 2022 Q4 | 99.01 Million EUR | 88.71% |
| 2022 Q1 | 68.7 Million EUR | 17.88% |
| 2022 FY | 255.84 Million EUR | 40.91% |
| 2022 Q3 | 52.47 Million EUR | 47.16% |
| 2022 Q2 | 35.65 Million EUR | -48.11% |
| 2021 Q4 | 58.28 Million EUR | -2.94% |
| 2021 Q1 | 29.6 Million EUR | 52.56% |
| 2021 Q2 | 33.63 Million EUR | 13.61% |
| 2021 Q3 | 60.04 Million EUR | 78.54% |
| 2021 FY | 181.57 Million EUR | 143.13% |
| 2020 FY | 74.68 Million EUR | 74.32% |
| 2020 Q1 | 15.13 Million EUR | 73.26% |
| 2020 Q4 | 19.4 Million EUR | -13.31% |
| 2020 Q2 | 17.76 Million EUR | 17.37% |
| 2020 Q3 | 22.38 Million EUR | 26.04% |
| 2019 Q1 | 7.53 Million EUR | 1856.36% |
| 2019 Q2 | 10.22 Million EUR | 35.69% |
| 2019 FY | 42.84 Million EUR | 145.41% |
| 2019 Q4 | 8.73 Million EUR | -46.61% |
| 2019 Q3 | 16.35 Million EUR | 60.06% |
| 2018 Q4 | 385 Thousand EUR | -95.99% |
| 2018 FY | 17.45 Million EUR | -8.16% |
| 2018 Q3 | 9.59 Million EUR | 4555.34% |
| 2018 Q2 | 206 Thousand EUR | -97.17% |
| 2018 Q1 | 7.27 Million EUR | 1087.11% |
| 2017 Q2 | 10.7 Million EUR | 46.44% |
| 2017 Q1 | 7.3 Million EUR | 39.87% |
| 2017 FY | 19 Million EUR | -32.83% |
| 2017 Q4 | 613 Thousand EUR | 58.81% |
| 2017 Q3 | 386 Thousand EUR | -96.39% |
| 2016 Q3 | 3.44 Million EUR | -62.8% |
| 2016 Q2 | 9.25 Million EUR | -10.73% |
| 2016 FY | 28.3 Million EUR | 29.57% |
| 2016 Q4 | 5.22 Million EUR | 51.71% |
| 2016 Q1 | 10.37 Million EUR | 170.24% |
| 2015 Q3 | 3.39 Million EUR | -54.59% |
| 2015 Q1 | 7.14 Million EUR | 35.03% |
| 2015 FY | 21.84 Million EUR | -21.13% |
| 2015 Q4 | 3.83 Million EUR | 13.15% |
| 2015 Q2 | 7.47 Million EUR | 4.59% |
| 2014 Q1 | 6.88 Million EUR | 37.25% |
| 2014 FY | 27.69 Million EUR | 8.72% |
| 2014 Q3 | 5.75 Million EUR | -41.04% |
| 2014 Q4 | 5.28 Million EUR | -8.1% |
| 2014 Q2 | 9.76 Million EUR | 41.73% |
| 2013 Q2 | 9.16 Million EUR | 53.09% |
| 2013 Q3 | 5.29 Million EUR | -42.19% |
| 2013 Q4 | 5.01 Million EUR | -5.3% |
| 2013 FY | 25.47 Million EUR | 17.51% |
| 2013 Q1 | 5.98 Million EUR | -26.03% |
| 2012 Q2 | 8.17 Million EUR | 51.1% |
| 2012 FY | 21.67 Million EUR | 14.18% |
| 2012 Q3 | 4.06 Million EUR | -50.26% |
| 2012 Q4 | 8.09 Million EUR | 99.14% |
| 2012 Q1 | 5.4 Million EUR | 7.17% |
| 2011 Q2 | 8.93 Million EUR | 78.31% |
| 2011 Q3 | 3.15 Million EUR | -64.7% |
| 2011 FY | 18.98 Million EUR | -26.99% |
| 2011 Q4 | 5.04 Million EUR | 60.12% |
| 2011 Q1 | 5 Million EUR | 558.61% |
| 2010 Q4 | -1.09 Million EUR | -116.11% |
| 2010 Q1 | 6.13 Million EUR | 0.0% |
| 2010 Q2 | 14.18 Million EUR | 131.13% |
| 2010 FY | 26 Million EUR | 87.09% |
| 2010 Q3 | 6.77 Million EUR | -52.21% |
| 2009 FY | 13.89 Million EUR | -50.92% |
| 2008 FY | 28.32 Million EUR | 53.6% |
| 2007 FY | 18.43 Million EUR | 427.86% |
| 2006 FY | 3.49 Million EUR | -100.0% |
| 2005 FY | 291.58 Billion EUR | 17158.37% |
| 2004 FY | 1.68 Billion EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | 7051.861% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 23748.135% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 8482.575% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 1334.123% |
| GB Sciences, Inc. | -1.42 Million USD | 15605.287% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 6568.586% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 100179.972% |
| Skye Bioscience, Inc. | -13.67 Million USD | 1711.01% |
| Zenith Capital Corp. | -8.94 Million USD | 2562.865% |
| Agentix Corp. | -1.37 Million USD | 16156.354% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 4466.235% |
| Biomind Labs Inc. | -1 Million USD | 21915.902% |
| ContraFect Corporation | -56.88 Million USD | 487.164% |
| CSL Limited | 3.7 Billion USD | 94.05% |
| CytoDyn Inc. | -18.05 Million USD | 1319.703% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 11913.857% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 56637.721% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 496.797% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 53112.066% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 14438.996% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 32162.596% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -169.088% |
| SQZ Biotechnologies Company | -75.82 Million USD | 390.477% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 11187.658% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 406.82% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 7826.836% |
| Mesoblast Limited | -84.14 Million USD | 361.749% |
| Marizyme, Inc. | -34.08 Million USD | 746.162% |
| Genus plc | 6.4 Million USD | -3341.469% |
| Pharming Group N.V. | -4.87 Million USD | 4613.823% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 2737.772% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 15810.087% |
| IMV Inc. | -38.67 Million USD | 669.551% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 8106.794% |
| MultiCell Technologies, Inc. | -722.81 USD | 30472008.247% |
| ONE Bio Corp. | 13.68 Million USD | -1509.862% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 473.375% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -6121.864% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 7691.693% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 3413.079% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 735456.571% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1487.887% |
| Alpha Cognition Inc. | -9.7 Million USD | 2369.349% |
| Enzolytics Inc. | -2.14 Million USD | 10350.093% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 151.818% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 21197.126% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 7644.382% |
| Genscript Biotech Corporation | -415.79 Million USD | 152.972% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -4381.434% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 84254.421% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 9070.491% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 128520.845% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 11086.568% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -2160.764% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 4935.724% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 5979.054% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 22482.331% |
| EV Biologics, Inc. | -483.06 Thousand USD | 45695.389% |
| Q BioMed Inc. | -3.44 Million USD | 6492.297% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 17636.146% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 500.663% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 2931.403% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 11496.712% |
| HST Global, Inc. | -140.9 Thousand USD | 156411.61% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 16593.102% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 19679.769% |
| Halberd Corporation | -75.05 Thousand USD | 293576.349% |
| Resverlogix Corp. | -12.74 Million USD | 1827.618% |
| Cell Source, Inc. | -4.32 Million USD | 5192.171% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 14045.82% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | -3190.87% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 1264401.705% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | 9028.878% |
| Kadimastem Ltd | -3.04 Million USD | 7344.602% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 5296.614% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 121462.096% |
| LadRx Corporation | -3.82 Million USD | 5860.344% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 32162.596% |
| Affymax, Inc. | -15.04 Million USD | 1563.871% |
| Itoco Inc. | -919.14 Thousand USD | 24063.052% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 19783.11% |
| Mobile Lads Corp. | -554.55 Thousand USD | 39817.609% |
| International Stem Cell Corporation | -663 Thousand USD | 33320.814% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 5865.59% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 875165.554% |
| Qrons Inc. | -643.67 Thousand USD | 34318.094% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 39102.13% |
| SYBLEU INC | -149.18 Thousand USD | 147743.116% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 9977.397% |
| Rebus Holdings, Inc. | -664 Thousand USD | 33270.783% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 12226.387% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 418515.653% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 1082961.357% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 707.329% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 13712.732% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 30032.526% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 7179.846% |
| Neutra Corp. | -229.48 Thousand USD | 96077.097% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 1355.796% |
| PureTech Health plc | -146.19 Million USD | 250.654% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 1124.861% |
| IXICO plc | -1.43 Million USD | 15427.349% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 2420.662% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 280.824% |
| CSL Limited | 3.81 Billion USD | 94.222% |
| Cellectis S.A. | -108.85 Million USD | 302.333% |